Home » Topics » BioWorld Science, Hematologic

BioWorld Science, Hematologic
RSS

FDA approves revised labeling for Integrilin

June 12, 2001

The Medicines Company provides update on Angiomax clinical trials

June 12, 2001

Cor synthesizes selective factor Xa inhibitors

June 11, 2001

Benzoic acid-based integrin antagonists designed by Meiji Seika

June 11, 2001

Aventis presents new series of anticoagulant/antithrombotic compounds

June 8, 2001

The Medicines Company and Ferrer establish Angiomax collaboration

June 7, 2001

Corvas completes phase IIa PTCA trial with rNAPc2

June 7, 2001

Long-term benefits of Integrilin emerge from ESPRIT study

June 7, 2001

Avigen receives FDA approval to begin second trial of Coagulin-B for hemophilia B

June 6, 2001

Highly selective factor Xa inhibitors emerge from R&D at Corvas

May 31, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 30, 2026.
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Regulatory actions for July 27, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Alfasigma,...